Eisai Co., Ltd. (TYO:4523)
4,569.00
-36.00 (-0.78%)
Oct 22, 2025, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 202.65B JPY in the quarter ending June 30, 2025, with 7.21% growth. This brings the company's revenue in the last twelve months to 803.02B, up 9.43% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
803.02B
Revenue Growth
+9.43%
P/S Ratio
1.60
Revenue / Employee
73.56M
Employees
10,917
Market Cap
1.29T
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Takeda Pharmaceutical Company | 4.48T |
Otsuka Holdings | 2.40T |
Astellas Pharma | 1.94T |
Daiichi Sankyo Company | 1.92T |
Chugai Pharmaceutical | 1.20T |
Terumo | 1.04T |
Olympus | 969.02B |
HOYA Corporation | 876.09B |
Eisai News
- 8 days ago - LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Benzinga
- 13 days ago - Eisai Co., Ltd. (ESAIY) Special Call - Slideshow - Seeking Alpha
- 15 days ago - Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
- 15 days ago - Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment - Nasdaq
- 15 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - Benzinga
- 15 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - PRNewsWire
- 23 days ago - Eisai : LEQEMBI Approved In China For Monthly IV Maintenance Dosing In Early Alzheimer's Treatment - Nasdaq
- 4 weeks ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - Benzinga